Discover how a root-cause, individualized approach can help women overcome insulin resistance and restore metabolic flexibility for lasting health.

The truth became unavoidable: the traditional school setting was never going to be able to meet our daughter's needs.

The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a soft sales outlook weighed on a medical device firm's stock.

The continuous glucose monitoring powerhouse saw its share price drop a frightening 17% in the first two hours of trading on Oct. 31, pushing it down by one-third from its peak of $89.53 in late July.

Aptiva Medical will use its recent acquisition of VeraMed Health and a laser focus on continuous glucose monitors (CGMs) to position itself as a leader in the market, says ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

DexCom may be a major player in the market for continuous glucose monitors, but that doesn’t means it’s shielded from ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

As people around the world seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow ...

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated ...